Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock Life Science Fall Summit - one week away!

On October 25 & 26 it is once again time for the go-to life science partnering event in the Nordics: the BioStock Life Science Fall Summit! The packed two-day event, at Medicon Village in Lund, featurs around 40 thrilling life science companies showcasing their projects and innovations to investors and potential partners. The Summit also gives space for Expert Insights sessions, where industry experts and investors will offer their valuable advice and experiences.Have you noticed any trends on the stock markets lately? How are listed life science companies handling the current financial

Gradientech expands its distribution network in Europe

The diagnostic company Gradientech today announces an exclusive distribution agreement with Iberlab for the commercialisation of QuickMIC® in Portugal.Iberlab is a leading supplier of diagnostic solutions and consumables to clinical laboratories on the Portuguese market. "At Iberlab, we aim to meet our customers’ requirements at the highest level. It is our strong ambition to provide diagnostic solutions to satisfy the needs of the clinical laboratory. Adding the product line from Gradientech is therefore a strong addition to our portfolio. The QuickMIC system fits our focus perfect as we

Equativ Integrates NinaData’s Generative AI Audiences to Enhance Consumer Buying Intent Prediction

Equativ's Buyer Connect platform, together with NinaData's large language model (LLM) for predictive buying, shows advertisers exactly where to reach their audiences – in a 100% privacy-first environment.Finnish buying intent data platform, NinaData , has announced its integration with Equativ , the leading independent adtech platform. NinaData's advanced contextual targeting and buying intent capabilities are now available in Equativ’s Buyer Connect (EBC) digital ad curation platform – enabling media buyers to more effectively target their

Notice to attend the Extraordinary General Meeting of John Mattson Fastighetsföretagen AB (publ)

The shareholders of John Mattson Fastighetsföretagen AB (publ), reg. no. 556802-2858 (“John Mattson” or the “Company”), are hereby given notice of the Extraordinary General Meeting (the “EGM”) on 21 November 2023 at 2:00 p.m. in Malmstensalen at Campus Lidingö (Malmstenskolan), Larsbergsvägen 8, Lidingö. Entry and registration commences at 1:30 p.m.Right to participate at the EGM Shareholders wishing to participate at the EGM must: · be entered in the share register maintained by Euroclear Sweden AB ("Euroclear") on 13 November 2023, or alternatively, if the shares are nominee-

Nixu Corporation: CEO’s review for Q3 2023

Nixu Corporation Stock Exchange Release, October 18, 2023, at 8:30 am EESTMacroeconomic situation continues to impact growth July–September 2023: · Revenue EUR 13.1 million (Q3/2022: EUR 14.4 million); change -9% · EBIT EUR -805 thousand (Q3/2022: EUR 642 thousand) · Adjusted EBIT EUR -548 thousand (Q3/2022: EUR 642 thousand) January–September 2023: · Revenue EUR 45.0 million (Q3/2022: EUR 43.0 million); growth 5% · EBIT EUR -1,888 thousand (Q3/2022: EUR 88 thousand) · Adjusted EBIT EUR 159 thousand (Q3/2022: EUR 63 thousand) Financial guidance for 2023:

PharmNovo signs agreement with Worldwide Clinical Trials for phase IIa study of PN6047 in neuropathic pain

PharmNovo, a Swedish pharmaceutical company developing neuropathic pain treatments, announces its collaboration with Worldwide Clinical Trials, a full-service contract research organisation (CRO), to conduct the phase IIa study of PN6047.The study is planned to start in 2024.In the upcoming phase IIa study, PharmNovo will investigate the safety, tolerability, pharmacokinetics, and efficacy of their drug candidate PN6047 for individuals affected by neuropathic pain and experiencing Mechanical Allodynia. This distressing symptom, caused by nerve injury, often disrupts daily life and sleep.

The Board of Directors of John Mattson has resolved on a fully guaranteed rights issue of approximately SEK 1,250 million to strengthen its financial position and enable value-creating investments

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER COUNTRY OR JURISDICTION TO WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS OR WOULD REQUIRE THE PREPARATION OR REGISTRATION OF ADDITIONAL DOCUMENTATION OR REQUIRE ANY OTHER ACTION TO BE TAKEN, IN ADDITION TO THE REQUIREMENTS OF SWEDISH LAW. THIS PRESS RELEASE IS NOT A PROSPECTUS BUT AN ANNOUNCEMENT IN CONNECTION WITH THE PLANNED NEW ISSUE OF

Curasight A/S reports positive preclinical results with uTREAT[®] in lung cancer (NSCLC)

· Preclinical studies show uTREAT[®] effective in treating non-small cell lung cancer (NSCLC) · Data follows recent announcement of positive preclinical results within glioblastoma and supports hypothesis that uTREAT[®] has treatment potential in additional solid tumors · Data highlights potential of company’s uPAR theranostic platform to combine diagnosis (uTRACE[®]) with more gentle and targeted treatment (uTREAT[®]) Copenhagen, October 18, 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) is pleased to announce preclinical data demonstrating preclinical proof

Volvo Group – the third quarter 2023

“In Q3 2023, the Volvo Group continued to deliver improved results, margins and profitability. Adjusted for currency, our net sales grew by 9% to SEK 132.4 billion and we increased the adjusted operating income to SEK 19.1 billion (11.9), corresponding to an adjusted operating margin of 14.4% (10.3). We have successfully mitigated cost inflation with price management and continued to handle disturbances in the supply chain. Return on capital employed increased to 33.7% (27.4),” says Martin Lundstedt, President and CEO.· In Q3 2023, net sales increased by 15% to SEK 132.4 billion (114.9).

BlueNord Announce Third Quarter 2023 Results

Oslo, 18 October 2023: BlueNord ASA ("BlueNord" or the "Company") today published its third quarter 2023 results. During the quarter, the Company delivered strong operational and financial performance.  Tyra II de-risking continued and BlueNord now expects the revised start-up strategy to accelerate plateau production into Q2 2024, delivering greater volumes from Tyra during 2024 than what was previously communicated through the Company’s long-term production outlook.   Highlights: · Second quarter net hydrocarbon production of 24.7 mboepd, in upper end of quarterly guidance ·

Handelsbanken’s Interim Report January – September 2023

· Operating profit increased by 42% to SEK 27,265m (19,251) · Return on equity increased to 16.2% (12.5) · The C/I ratio improved to 36.8% (42.3) · Continued good credit quality with a credit loss ratio of 0.01% (0.00) · Strong financial position with a common equity tier 1 ratio of 19.4% (19.0)  * Items affecting comparability: Reversal of VAT paid in conjunction with sale of card acquiring operations (other income) SEK 141m and (net fee and commission income) SEK 17m (Q2 2023); funding cost relating to discontinued operations in Finland (net interest income)

Aker Carbon Capture awarded feasibility study by major waste-to-energy player in France

Aker Carbon Capture has been awarded a feasibility study to implement carbon capture at a waste-to-energy facility in France. The planned capture capacity will be approximately 200,000 tonnes CO2 per year and will be based on two Just Catch 100 carbon capture units. Year-to-date, Aker Carbon Capture has now contracted studies, Mobile Test Unit campaigns and pre-FEEDs for a combined capture capacity of 8.7 million tonnes of CO2 per year.“We are excited to be working on this decarbonization project, which will be Aker Carbon Capture’s first study in France. Carbon capture, usage, and storage (

Camurus’ Nomination Committee appointed for the Annual General Meeting 2024

Lund — 18 October 2023 — Camurus today announced that the Nomination Committee for the Annual General Meeting (AGM), 2024 consists of the following persons, who together represent about 47.9 percent of the total number of shares and votes in Camurus based on the last known shareholder information: · Per Sandberg, appointed by Sandberg Development AB, · Arne Lööw, appointed by Fjärde AP-fonden, · Magnus Welander, appointed by Fredrik Tiberg, and · Per Olof Wallström, Chairman of the Board of Camurus The Nomination Committee’s proposals will be presented in the Notice to the

Circio strengthens its focus on next generation circular RNA therapeutics with additional cost reductions

· Closing of Finnish subsidiary · The Board of Directors will be reduced from seven to four persons · The management team will be restructured to five persons · Cost savings will extend the runway on existing resourcesEarlier this year, Circio announced a strategic shift to prioritize and accelerate its innovative and differentiated circVec circular RNA platform. To establish a strong foundation for building a novel pre-clinical pipeline, the company's activities and organization have been further optimized to support and reinforce circVec development in rare disease and vaccines.

Interim Report January – September 2023

“During the third quarter, TF Bank's operating profit amounted to SEK 131 million, including a provision for restructuring costs of SEK 16 million. The underlying profitability improved during the quarter, partly due to implemented price increases and controlled lower lending growth. The loan portfolio increased by 4% in local currencies, particularly impacted by continued growth in the Credit Cards segment.”– Joakim Jansson, CEO January – September 2023 compared to January – September 2022 · The loan portfolio amounted to SEK 17,404 million, compared to September 2022 the increase

Tele2 interim report third quarter 2023

Stockholm – Tele2 AB (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) today announces its consolidated results for the third quarter 2023.Highlights   · End-user service revenue of SEK 5.4 billion increased by 3% organically compared to Q3 2022 due to strong performance in the Baltics and Sweden B2B. Total revenue of SEK 7.3 billion remained unchanged organically compared to Q3 2022. · Underlying EBITDAaL of SEK 2.8 billion increased by 3% organically compared to Q3 2022 driven by end-user service revenue growth and cost savings related to the Business Transformation Program,

Change in the YIT Management Team: Tom Ekman to leave YIT

YIT Corporation Stock Exchange Release 18 October 2023 at 08:00 a.m.Change in the YIT Management Team: Tom Ekman to leave YIT Tom Ekman, EVP, Business Premises segment, is leaving YIT and will pursue his career outside of the company. He leaves YIT on 18 October 2023. ”I warmly thank Tom for his important contribution and long career at YIT. Tom has had a major role in YIT’s transformation, and he has strengthened the company’s position, especially in demanding life cycle projects. Together with his team, Tom has laid a solid foundation for customer-focused and effective operations in

LIAN LI Introduces Premium CPU Coolers Powered by Asetek’s Most Advanced Liquid Cooling Technology to Date

Galahad II LCD AIOs from LIAN LI Provide Excellent Performance, Silent Operation, and CustomizabilityAalborg, Denmark – October 18, 2023 –– Asetek, innovator of gaming hardware for next-level immersive gaming experiences and the creator of the all-in-one (AIO) liquid cooler, today announced that new OEM Partner LIAN LI makes available its Galahad II LCD CPU Coolers, leveraging the superior thermal and acoustic performance and reliability associated with Asetek’s most advanced technology to date. The Galahad II LCD AIOs will enable enthusiasts to boost CPU overclocking capability for extreme

Lundin Mining Pre-Announces Certain Items Impacting the Third Quarter 2023 Results

VANCOUVER, BC, October 17, 2023 /CNW/ - (TSX: LUN; Nasdaq Stockholm: LUMI) Lundin Mining Corporation (“Lundin Mining” or the “Company”) is introducing a process of pre-announcing certain items impacting the Company’s quarterly earnings, adjusted earnings before interest, taxes, depreciation and amortization (“adjusted EBITDA”)[1], adjusted earnings1 and adjusted earnings per share1. Items of significant impact in the third quarter 2023 are expected to include unaudited foreign exchange and trading gains on debt and equity investments supporting the capital funding for the Josemaria

Nordea Bank Abp: Repurchase of own shares on 17.10.2023

Nordea Bank AbpStock exchange release – Changes in company’s own shares17.10.2023 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 17.10.2023 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |48,507 |10.55 |511,680.94

Harebrained Schemes and Paradox Interactive to part ways as the Seattle-based developer seeks new opportunities

Paradox Interactive (Paradox) and Harebrained Schemes (HBS) – developers of the Shadowrun trilogy, BATTLETECH and The Lamplighters League – have decided to part ways on 1 January 2024. The separation is the result of a mutual agreement, stemming from each party’s strategic and creative priorities. Paradox will retain ownership of The Lamplighters League and other games developed by the studio. HBS will seek new publishing, partnership, and investment opportunities.  “Paradox has refocused its strategy towards its core niches within strategy and management games with endless qualities,”

Trophy Games Development A/S launch new share buyback program

Company Announcement No. 9-2023  Copenhagen, 17 October 2023 *Contains Inside Information*  The Board of Directors of Trophy Games Development A/S has decided to exercise the authority to buy back shares granted by the Annual General Meeting on 21 March 2023.  The authority is valid until next year’s general meeting. It covers a total nominal value not exceeding 10% of the share capital at the market price applicable at the time of acquisition with a deviation of up to 10%.  Purpose The company intends to use share buybacks as a supplement to dividends to adjust the

Natural ingredient leaders combine to launch new bioactives business

The Oterra Group announces the launch of Akay Bioactives: a new brand for its business unit offering clinically substantiated actives, specialty actives, and botanical extracts for the health and nutrition industry.The Oterra Group, the world’s leading supplier of natural colors, completed its acquisition of Akay Natural Ingredients, a prominent natural ingredients manufacturer, in October 2022. Newly formed Akay Bioactives integrates Akay’s Spiceuticals business and the Oterra Group’s NutriPhy business into one portfolio.“I’m extremely excited about the creation of Akay Bioactives,” said

Buy-back of shares in MTG during week 41, 2023

During the period between 9 and 13 October 2023 Modern Times Group MTG AB (publ) (LEI code 549300E8NDODRSX29339) (“MTG”) repurchased, in total, 125,017 own class B shares (ISIN code SE0018012494) under the share repurchase program initiated by the Board of Directors to deliver shareholder value and to optimize the capital structure of the company.The share buy-backs form a part of the share repurchase program of a maximum of 6,283,278 shares for a maximum amount of SEK 300 million, which MTG announced on 1 September 2023. The share repurchase program, which runs from 4 September 2023 until

There are no items matching the current filter
There are no more items matching the current filter
Back to top